Polysaccharide peptide (PSP) acts by upregulating the TLR4-TIRAP/MAL-MyD88 signaling pathway in peripheral blood mononuclear cells (PBMCs) from breast cancer patients, inducing the secretion of IL-12, IL-6, and TNF-α, thus serving as an immune adjuvant (90). Here, MYD88 is linked to breast cancer.